Compare Citius Pharmaceuticals Inc (CTXR) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Uranium Energy Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: Uranium Energy Corp is far larger — about 332.6× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 10,888,578). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Uranium Energy Corp for 37 Days on average.
| CTXR | UEC | |
|---|---|---|
Market Cap | $13.62M | $4.53B |
Volume | 132,438 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $1.82 | $20.14 |
52-Week Low | $0.48 | $9.04 |
Typical Hold Time | 17 Days | 37 Days |
Enterprise Value | $3.79M | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Uranium Energy (UEC) trades at $9.19, down 2.96% in the last session. The stock shows bearish technical signals with negative earnings momentum, posting losses in recent quarters despite revenue growth. The company is expanding its US uranium mining operations with two active mines, benefiting from increased government demand for domestic nuclear fuel. Analyst sentiment remains overwhelmingly positive with 87.5% buy ratings and a $16.06 consensus price target, though fundamental metrics show significant losses with a -368.62% net income margin.
UEC presents a high-risk, high-reward opportunity with strong Wall Street support but concerning financials. The bullish case hinges on nuclear energy expansion and domestic uranium demand growth, while risks include sustained operational losses, unproven production sustainability, and heavy reliance on financing activities. Current valuation appears stretched given negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
